{"id":39791,"date":"2013-09-07T17:01:06","date_gmt":"2013-09-07T21:01:06","guid":{"rendered":"http:\/\/1boringoldman.com\/?p=39791"},"modified":"2013-09-07T17:04:27","modified_gmt":"2013-09-07T21:04:27","slug":"who-was-that-guy","status":"publish","type":"post","link":"https:\/\/1boringoldman.com\/index.php\/2013\/09\/07\/who-was-that-guy\/","title":{"rendered":"who was that guy?…"},"content":{"rendered":"

Who was that guy? The one in the video that seemed so outrageous [a deal-breaker?…<\/a>, a window…<\/a>]. And where was that meeting? What was it about?<\/p>\n

<\/a><\/div>\n\n\n
\n
Neal Parker<\/font><\/strong><\/a><\/div>\n

<\/p>\n

Section Head Legal – Biologics Strategic Development, Abbvie<\/strong><\/div>\n

<\/p>\n

Neal Parker is a U.S. lawyer specializing in drug and biologic regulatory issues. He began his career more than 20 years ago representing international and domestic clients in matters subject to U.S. Food and Drug Administration (FDA) regulation. In 1994, he left private practice to join the FDA, where he served as a senior lawyer in the agency’s Office of the Chief Counsel providing advice to the FDA Commissioner and Center for Drug Evaluation and Research (CDER) Director on novel and emerging issues of FDA law such as biologics, dietary supplements and combination products. At FDA, Neal handled FDA enforcement matters, rulemaking and guidance issues, and also litigated on behalf of the FDA numerous defensive, seizure, and injunctive enforcement actions involving unapproved drugs, generic drugs, dietary supplements, adulterated and otherwise violative medical devices, and biologic products. In 2001, Neal left FDA and joined Abbott laboratories, where he worked on world-wide biopharmaceutical and medical device legal regulatory issues. <\/div>\n<\/td>\n<\/tr>\n<\/table>\n
hat tip to Jamzo<\/strong> <\/div>\n","protected":false},"excerpt":{"rendered":"

Who was that guy? The one in the video that seemed so outrageous [a deal-breaker?…, a window…]. And where was that meeting? What was it about? Neal Parker Section Head Legal – Biologics Strategic Development, Abbvie Neal Parker is a U.S. lawyer specializing in drug and biologic regulatory issues. He began his career more than […]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_bbp_topic_count":0,"_bbp_reply_count":0,"_bbp_total_topic_count":0,"_bbp_total_reply_count":0,"_bbp_voice_count":0,"_bbp_anonymous_reply_count":0,"_bbp_forum_subforum_count":0,"footnotes":""},"categories":[2],"tags":[],"class_list":["post-39791","post","type-post","status-publish","format-standard","hentry","category-politics"],"_links":{"self":[{"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/posts\/39791","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/comments?post=39791"}],"version-history":[{"count":14,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/posts\/39791\/revisions"}],"predecessor-version":[{"id":39805,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/posts\/39791\/revisions\/39805"}],"wp:attachment":[{"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/media?parent=39791"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/categories?post=39791"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/tags?post=39791"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}